Center for Molecular Imaging, The Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center, Houston, TX 77030, USA.
Bioorg Med Chem. 2011 Jun 15;19(12):3769-76. doi: 10.1016/j.bmc.2011.04.054. Epub 2011 May 6.
Optical imaging possesses similar sensitivity to nuclear imaging and has led to the emergence of multimodal approaches with dual-labeled nuclear/near-infrared (NIR) agents. The growing impact of (68)Ga (t(1/2)=68 min) labeled peptides on preclinical and clinical research offers a promising opportunity to merge the high spatial resolution of NIR imaging with the clinically-accepted positron emission tomography (PET). Previously, dual-labeled agents have been prepared with longer-lived radiometals and showed no detrimental effects on optical properties as a result of radiolabeling. In this study, we selected a peptide (M(2)) that targets MMP-2/9 and is dual-labeled with IRDye 800 CW and (68)Ga. Since (68)Ga chelation typically requires low pH (3.5-4) and elevated heating temperatures (95 °C), we sought to evaluate the impact of (68)Ga labeling on the optical properties of M(2). An efficient method for preparation of (68)Ga-M(2) was developed and reaction conditions were optimized. Stability studies in PBS, DTPA, and serum were performed and high levels of intact agent were evident under each condition. The addition of multiple reporters to a targeting agent adds further complexity to the characterization and validation and thus requires not only testing to ensure the agent is stable chemically and radiochemically, but also optically. Therefore, fluorescence properties were evaluated using a spectrofluorometer as well as by fluorescence detection via HPLC. It was determined that (68)Ga-labeling conditions did not impair the fluorescent properties of the agent. The agent was then used for in vivo imaging in a mouse model of heterotopic ossification (HO) with activated MMP-9 expression as an early biomarker which precedes mineralization. Although (68)Ga-complexation greatly reduced binding affinity of the peptide and negated tracer uptake on PET, NIR imaging showed consistent fluorescent signal that correlated to MMP-9 expression. This attests to the feasibility of using (68)Ga/NIR for dual-labeling of other peptides or small molecules for multimodality molecular imaging.
光学成像是一种与核成像具有相似敏感性的方法,并已导致出现具有双标记核/近红外(NIR)试剂的多模态方法。(68)Ga(t(1/2)=68 分钟)标记肽对临床前和临床研究的影响越来越大,为将 NIR 成像的高空间分辨率与临床可接受的正电子发射断层扫描(PET)相结合提供了一个很有前途的机会。以前,使用半衰期更长的放射性金属制备了双标记试剂,并且由于放射性标记,其光学性质没有受到不利影响。在这项研究中,我们选择了一种针对 MMP-2/9 的肽(M(2)),并用 IRDye 800CW 和(68)Ga 对其进行双标记。由于(68)Ga 螯合通常需要低 pH(3.5-4)和升高的加热温度(95°C),因此我们试图评估(68)Ga 标记对 M(2)光学性质的影响。开发了一种用于制备(68)Ga-M(2)的有效方法,并对反应条件进行了优化。在 PBS、DTPA 和血清中进行了稳定性研究,在每种条件下均显示出大量完整的试剂。向靶向试剂中添加多个报告器会增加其表征和验证的复杂性,因此不仅需要进行测试以确保试剂在化学和放射化学上稳定,而且还需要进行光学测试。因此,使用分光荧光计以及通过 HPLC 进行荧光检测来评估荧光特性。确定(68)Ga 标记条件不会损害试剂的荧光特性。然后,将该试剂用于 MMP-9 表达作为早期生物标志物的异位骨化(HO)的小鼠模型中的体内成像,该生物标志物先于矿化。尽管(68)Ga 络合物大大降低了肽的结合亲和力,并使 PET 上的示踪剂摄取为阴性,但 NIR 成像显示出与 MMP-9 表达一致的荧光信号。这证明了使用(68)Ga/NIR 对其他肽或小分子进行双标记以进行多模态分子成像的可行性。